At the end of three consecutive monthly loading doses of anti-VEGF therapy, eyes with residual IRF (in combination with SRF) averaged 20/180 while eyes with no fluid (either SRF or IRF ...
Data from the ATMOSPHERE ® and ASCENT ™ pivotal trials evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet AMD are ... of fluid in the retina.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback